FDA approves zilganersen (Zanvastro) as first treatment for Alexander disease

The FDA has approved zilganersen (Zanvastro), an antisense oligonucleotide, for the treatment of Alexander disease (AxD) in pediatric and adult patients, marking the first approved therapy for this ultra-rare, progressive neurological disorder.¹ Until now, management of AxD has been limited to supportive care.¹

“For patients with Alexander disease and their families, there have been no approved treatment options — only supportive care while the disease progresses,” said Emily Freilich, MD, director of the Division of Neurology I in the FDA’s Center for Drug Evaluation and Research. “Today’s approval is a landmark moment for this community, offering the first therapy that addresses the underlying cause of this rare and serious disease.”¹

Zilganersen trial design and efficacy in Alexander disease

Approval rests on a multicenter, randomized, controlled study (NCT04849741) enrolling 49 pediatric and adult patients with genetically confirmed AxD, plus an open-label substudy of 4 patients younger than 2 years.¹ Broader reporting places total pivotal enrollment at 54 participants ages 1.5 to 53 years, randomized 2:1 to drug or control.² Zanvastro is administered intrathecally every 3 months by a trained health care professional.¹

In patients 5 years and older with measurable gait impairment at baseline, zilganersen produced a statistically significant improvement in walking speed at week 61 versus untreated controls — a 33.3% least-squares mean difference on the 10-Meter Walk Test (P = .0412).^1,3 Because gait speed is unreliable in children aged 2 to 4 years, the FDA instead used a motor-function composite of standing, walking, running, and jumping; treated children improved on this measure while controls declined.¹ An exploratory analysis also linked treatment to a 33.6% reduction in plasma GFAP at week 61, consistent with the drug's mechanism.³

Evidence in patients younger than 2 years was limited by disease rarity and lack of a concurrent control arm. The FDA instead relied on pharmacokinetic modeling showing expected exposure similar to older children at the same dose, plus safety data from the 4 infants and from older pediatric trial participants.¹

Disease burden and unmet need in Alexander disease

AxD results from mutations in the gene encoding glial fibrillary acidic protein (GFAP); the abnormal protein accumulates in astrocytes and progressively damages the nervous system.¹ Estimated prevalence is under 1 in a million, with some estimates as low as 1 per 1 to 3 million worldwide, and onset can occur at any age.^1,4 Manifestations include seizures, loss of developmental milestones, gait disturbance, muscle weakness, and elevated intracranial pressure; the disease is often ultimately fatal.^1,4

Mechanism and regulatory pathway for zilganersen

Zilganersen binds GFAP messenger RNA and recruits RNase H to degrade it, reducing abnormal protein production before it accumulates in astrocytes.^1,4 This targets the underlying molecular driver of AxD rather than downstream symptoms. The drug advanced under Orphan Drug, Fast Track, Breakthrough Therapy, and Rare Pediatric Disease designations, the last of which confers a Priority Review Voucher to sponsor Ionis Pharmaceuticals.¹

Safety profile and interpretive context

The most common adverse effects were vomiting, back pain, cough, headache, and post-lumbar puncture syndrome.¹ Aseptic meningitis has also been reported; the FDA advises monitoring for meningitis symptoms and reviewing full prescribing information before treatment.¹ The primary gait-speed benefit, while statistically significant, was modest (P = .0412), making the exploratory GFAP biomarker and motor-composite findings useful corroborating signals rather than standalone proof of benefit.

Limitations and next steps

The controlled trial period covered 61 weeks, and applicability in patients younger than 2 years relies on modeling and single-arm safety data rather than controlled efficacy comparison. Longer-term outcomes will depend on the trial's open-label and extension phases. Clinicians should confirm a genetically confirmed GFAP variant, weigh the intrathecal administration burden, and counsel families that this evidence, though a first for AxD, comes from a small population typical of ultra-rare disease programs.

References

1. US Food and Drug Administration. FDA approves first drug to treat Alexander disease. Published September 3, 2026. Accessed September 3, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-alexander-disease

2. NeurologyLive. FDA accepts zilganersen new drug application for priority review in Alexander disease. Accessed September 3, 2026. https://www.neurologylive.com/view/fda-accepts-zilganersen-new-drug-application-priority-review-alexander-disease

3. Ionis Pharmaceuticals. Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting. Accessed September 3, 2026. https://ir.ionis.com/news-releases/news-release-details/ionis-presents-new-data-pivotal-study-zilganersen-alexander

4. ClinicalTrialsDaily. Zilganersen ASO reverses functional decline in Alexander disease ahead of 2026 PDUFA. Published April 21, 2026. Accessed September 3, 2026. https://www.clinicaltrialsdaily.com/zilganersen-aso-alexander-disease-pdufa/